Results 321 to 330 of about 2,830,257 (398)

Real‐world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta‐analysis

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to summarize and pool real‐world evidence on the clinical effectiveness and safety of galcanezumab. Background Migraine is a disabling primary headache disorder. Several drugs that target calcitonin gene‐related peptide, such as galcanezumab, have recently been developed.
Jaime Fernández‐Bravo‐Rodrigo, Carlos Pascual‐Morena, Alicia Saz‐Lara, Irene Martínez‐García, Carla Geovanna Lever‐Megina, Silvana Patiño‐Cardona, Amparo Flor‐García, Iván Cavero‐Redondo   +7 more
wiley   +1 more source

Treatment of thoracic outlet syndrome to relieve chronic migraine. [PDF]

Clin Anat
Cha YH, Randall L, Weber J, Ahn S.
europepmc   +1 more source

Engagement and predictors of use of a smartphone app for migraine self‐management: A secondary analysis of the EMMA trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this secondary analysis was to examine engagement with a mobile app for migraine self‐management and to identify predictors of migraine app usage. Background Migraine self‐monitoring and behavioral strategies are central components in migraine self‐management, but patient adherence often remains a challenge. Recently,
Stefanie Lysk, Daniel Pach, Tatjana Tissen‐Diabaté, Simon Scholler, Claudia M. Witt   +4 more
wiley   +1 more source

Profiling chronic migraine patients according to clinical characteristics: a cluster analysis approach. [PDF]

Front Neurol
Katsuki M, Matsumori Y, Kawamura S, Kashiwagi K, Koh A, Goto T, Kaneko K, Wada N, Yamagishi F.   +8 more
europepmc   +1 more source

False nonresponders to anti‐calcitonin gene‐related peptide monoclonal antibodies: A real‐world analysis beyond migraine frequency reduction

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Reimbursement criteria for anti‐calcitonin gene‐related peptide (CGRP) monoclonal antibodies (MAbs) typically rely on predefined reductions in monthly migraine days (MMD). However, this approach may fail to capture the full spectrum of treatment benefits, potentially leading to premature discontinuation in patients ...
Albert Muñoz‐Vendrell, Sergio Campoy‐Díaz, Patricia Díaz‐Corta, Lidia Termens, Jaume Campdelacreu, Joan Prat, Jordi Sanahuja, Mariano Huerta‐Villanueva   +7 more
wiley   +1 more source

Exploring the Impact of Osteopathic Manipulative Treatment on Chronic Migraine Relief: A Case Study. [PDF]

Cureus
Lahlou Y, Aamir M, Shadiack V.
europepmc   +1 more source

A retrospective audit of the real‐world safety and effectiveness profile of eptinezumab for treatment‐resistant chronic migraine in Australia

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To describe the real‐world safety, tolerability, and effectiveness of eptinezumab for chronic migraine prevention in Australia. Background Eptinezumab is a relatively new medication for treatment‐resistant chronic migraine prevention.
Lakshini Gunasekera, Shuli Cheng, Emma Foster, Shobi Sivathamboo, Terence O'Brien, Helmut Butzkueven, Jayashri Kulkarni, Elspeth Hutton   +7 more
wiley   +1 more source

Serum cytokines in primary new daily persistent headache and chronic migraine: a case control study. [PDF]

Front Neurol
Cheema S, Garr E, Mehta D, Chapman M, Hart M, Lunn MP, Iodice V, Matharu MS.   +7 more
europepmc   +1 more source

Evidence for brain glial activity in chronic migraine patients: a [¹¹C] PBR28 PET/MR study. [PDF]

Eur J Nucl Med Mol Imaging
Chang Y, Zhang X, Xiao S, Liu J, Wang Y, Song J, Fu H, Li Y, Su H, Yi H, Su W, Gao N, Zhao J, Wang R, Liu R.   +14 more
europepmc   +1 more source